KRAS and non-small cell lung carcinoma: For instance, ERK3 activity is required for KRAS-driven tumorigenesis in vitro, and ERK3 deficiency inhibits the oncogenic growth of KRAS (G12C)-mutant NSCLC in vivo, indicating the application of ERK3 inhibitors in KRAS (G12C)-driven tumours180.